357 related articles for article (PubMed ID: 30946858)
1. Trends in colonoscopy and fecal occult blood test use after the introduction of dual screening offers in Germany: Results from a large population-based study, 2003-2016.
Chen C; Stock C; Jansen L; Chang-Claude J; Hoffmeister M; Brenner H
Prev Med; 2019 Jun; 123():333-340. PubMed ID: 30946858
[TBL] [Abstract][Full Text] [Related]
2. Changes in colorectal cancer screening use after introduction of alternative screening offer in Germany: Prospective cohort study.
Guo F; Chen C; Schöttker B; Holleczek B; Hoffmeister M; Brenner H
Int J Cancer; 2020 May; 146(9):2423-2432. PubMed ID: 31291471
[TBL] [Abstract][Full Text] [Related]
3. Is the patient activation measure associated with adherence to colonoscopy after a positive fecal occult blood test result?
Azulay R; Valinsky L; Hershkowitz F; Magnezi R
Isr J Health Policy Res; 2018 Dec; 7(1):74. PubMed ID: 30577883
[TBL] [Abstract][Full Text] [Related]
4. Colonoscopy and fecal occult blood test use in Germany: results from a large insurance-based cohort.
Stock C; Ihle P; Schubert I; Brenner H
Endoscopy; 2011 Sep; 43(9):771-81. PubMed ID: 21830189
[TBL] [Abstract][Full Text] [Related]
5. Colorectal cancer screening behavior in women attending screening mammography: longitudinal trends and predictors.
Carlos RC; Fendrick AM; Abrahamse PH; Dong Q; Patterson SK; Bernstein SJ
Womens Health Issues; 2005; 15(6):249-57. PubMed ID: 16325138
[TBL] [Abstract][Full Text] [Related]
6. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies.
Inadomi JM; Vijan S; Janz NK; Fagerlin A; Thomas JP; Lin YV; Muñoz R; Lau C; Somsouk M; El-Nachef N; Hayward RA
Arch Intern Med; 2012 Apr; 172(7):575-82. PubMed ID: 22493463
[TBL] [Abstract][Full Text] [Related]
7. Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years.
Liang PS; Wheat CL; Abhat A; Brenner AT; Fagerlin A; Hayward RA; Thomas JP; Vijan S; Inadomi JM
Am J Gastroenterol; 2016 Jan; 111(1):105-14. PubMed ID: 26526080
[TBL] [Abstract][Full Text] [Related]
8. Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008.
Choi KS; Lee HY; Jun JK; Shin A; Park EC
J Gastroenterol Hepatol; 2012 Jun; 27(6):1070-7. PubMed ID: 22004224
[TBL] [Abstract][Full Text] [Related]
9. Faecal occult blood testing (FOBT)-based colorectal cancer screening trends and predictors of non-use: findings from the South Australian setting and implications for increasing FOBT uptake.
Todorov K; Wilson C; Sharplin G; Corsini N
Aust Health Rev; 2018 Feb; 42(1):45-52. PubMed ID: 28248632
[TBL] [Abstract][Full Text] [Related]
10. The compliance rate for the second diagnostic evaluation after a positive fecal occult blood test: A systematic review and meta-analysis.
Gingold-Belfer R; Leibovitzh H; Boltin D; Issa N; Tsadok Perets T; Dickman R; Niv Y
United European Gastroenterol J; 2019 Apr; 7(3):424-448. PubMed ID: 31019712
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer test use--Maryland, 2002-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(36):932-6. PubMed ID: 17851446
[TBL] [Abstract][Full Text] [Related]
12. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).
Katičić M; Antoljak N; Kujundžić M; Stamenić V; Skoko Poljak D; Kramarić D; Stimac D; Strnad Pešikan M; Samija M; Ebling Z
World J Gastroenterol; 2012 Aug; 18(32):4300-7. PubMed ID: 22969192
[TBL] [Abstract][Full Text] [Related]
13. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
Sharaf RN; Ladabaum U
Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
[TBL] [Abstract][Full Text] [Related]
15. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
[TBL] [Abstract][Full Text] [Related]
16. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
Tsoi KK; Ng SS; Leung MC; Sung JJ
Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
[TBL] [Abstract][Full Text] [Related]
18. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
19. Participation in colorectal cancer screening: a review.
Vernon SW
J Natl Cancer Inst; 1997 Oct; 89(19):1406-22. PubMed ID: 9326910
[TBL] [Abstract][Full Text] [Related]
20. Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.
Halm EA; Beaber EF; McLerran D; Chubak J; Corley DA; Rutter CM; Doubeni CA; Haas JS; Balasubramanian BA
J Gen Intern Med; 2016 Oct; 31(10):1190-7. PubMed ID: 27279097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
